Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2H7XD | ISIN: US8106481059 | Ticker-Symbol: 2SX
Tradegate
06.06.25 | 16:50
3,678 Euro
-0,11 % -0,004
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
SCPHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
SCPHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
3,6103,77006.06.
3,5303,83206.06.

Aktuelle News zur SCPHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15.05.ScPharmaceuticals targets CKD launch and rising Medicare fill rates to accelerate FUROSCIX growth trajectory26
14.05.scPharmaceuticals Inc. - 10-Q, Quarterly Report2
14.05.scPharmaceuticals Inc. - 8-K, Current Report1
14.05.scPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business Update66Generated net FUROSCIX® revenue of $11.8 million in the first quarter of 2025 Formally launched FUROSCIX in second approved indication, Chronic Kidney Disease, in April 2025 Autoinjector on track...
► Artikel lesen
13.05.Insights Ahead: scPharmaceuticals' Quarterly Earnings2
SCPHARMACEUTICALS Aktie jetzt für 0€ handeln
07.05.scPharmaceuticals Inc.: scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 20254
20.03.Analyst Expectations For scPharmaceuticals' Future9
20.03.ScPharmaceuticals outlines FUROSCIX expansion strategy with CKD launch in April 202515
19.03.scPharmaceuticals Inc. - S-8, Securities to be offered to employees in employee benefit plans2
19.03.scPharmaceuticals Inc. - 10-K, Annual Report1
19.03.scPharmaceuticals GAAP EPS of -$0.35 beats by $0.03, revenue of $12.2M beats by $0.02M6
19.03.scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update126scPharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31, 2024...
► Artikel lesen
19.03.scPharmaceuticals Inc. - 8-K, Current Report1
12.03.scPharmaceuticals Inc.: scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 20253
07.03.FDA approves scPharmaceuticals' Furoscix sNDA for oedema in CKD12
07.03.H.C. Wainwright maintains Buy on scPharmaceuticals stock, $18 target11
07.03.ScPharma: FDA Approves FUROSCIX For Treating Edema In Chronic Kidney Disease Patients7
10.01.scPharmaceuticals reports preliminary Q4 numbers11
10.01.scPharmaceuticals prognostiziert 99% Umsatzsprung im vierten Quartal3
10.01.scPharmaceuticals projects 99% Q4 revenue jum1
Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1